COVID-19 induced delays in regulatory inspections set back Biocon, Ltd.’s plans for biosimilar bevacizumab in the US, but the Indian firm underscored that the product partnered with Viatris Inc. can still quickly garner “good market share” in view of their “extremely competitive” position.
At the firm’s Q4 FY2021 earnings call, Biocon chairperson Kiran Mazumdar-Shaw said that 2020 was a “very difficult” year for...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
